When companies see growth opportunities, they reinvest. It's when they don't that they return money to shareholders.

Apple Inc. might have clocked a record high of $115 in the market, but that has not stopped some of the biggest hedge funds in the U.S from offloading their stakes in the company.

With the Allergan acquisition, Actavis will be able to strengthen its global presence especially in Canada, Europe and Southeast Asia and other high-value growth markets like China, India, the Middle East and Latin America.

The average large cap score is 68.31, above the four week moving average score of 67.91. The average large cap stock is trading -10.27% below its 52 week high, 2.75% above its 200 dma, has 3.57 days to cover held short, and is expected to see EPS growth of 10.77% next year.

As per the sources, Actavis has agreed to pay $215 to $220 per share for the Botox maker.

If you're following Valeant's proposed takeover (or merger) of Allergan and the lawsuit by Allergan against Valeant and notorious hedge fund manager William Ackman for insider trading, this is a must-read article.